Hematological oncology · 2022
Perspective: Pivotal translational hematology and therapeutic insights in chronic myeloid hematopoietic stem cell malignancies.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mughal Tariq I, Pemmaraju Naveen, Bejar Rafael, Gale Robert P, Bose Prithviraj, Kiladjian Jean-Jacques, Prchal Josef, Royston Daniel, Pollyea Daniel, Valent Peter, Brümmendorf Tim H, Skorski Tomasz, Patnaik Mrinal, Santini Valeria, Fenaux Pierre, Kucine Nicole, Verstovsek Srdan, Mesa Ruben, Barbui Tiziano, Saglio Guiseppe, Van Etten Richard A
Аннотация
Despite much of the past 2 years being engulfed by the devastating consequences of the SAR-CoV-2 pandemic, significant progress, even breathtaking, occurred in the field of chronic myeloid malignancies. Some of this was show-cased at the 15th Post-American Society of Hematology (ASH) and the 25th John Goldman workshops on myeloproliferative neoplasms (MPN) held on 9th-10th December 2020 and 7th-10th October 2021, respectively. The inaugural Post-ASH MPN workshop was set out in 2006 by John Goldman (deceased) and Tariq Mughal to answer emerging translational hematology and therapeutics of patients with these malignancies. Rather than present a resume of the discussions, this perspective focuses on some of the pivotal translational hematology and therapeutic insights in these diseases.